{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:02:39Z","timestamp":1789524159285,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10557-026-07892-5","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T02:32:43Z","timestamp":1780021963000},"page":"1849-1860","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effects of Dapagliflozin Combined with Sacubitril\/Valsartan on Cardiac Electrophysiology and Quantitative Myocardial Motion Parameters in Patients with Atrial Fibrillation and Heart Failure with Preserved Ejection Fraction"],"prefix":"10.1007","volume":"40","author":[{"given":"Tao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"issue":"18","key":"7892_CR1","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","volume":"81","author":"BA Borlaug","year":"2023","unstructured":"Borlaug BA, Sharma K, Shah SJ, Ho JE. Heart Failure With Preserved Ejection Fraction: JACC Scientific Statement. J Am Coll Cardiol. 2023;81(18):1810\u201334. https:\/\/doi.org\/10.1016\/j.jacc.2023.01.049. Epub 2023\/05\/04.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"7892_CR2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12916-023-02764-3","volume":"21","author":"L Fauchier","year":"2023","unstructured":"Fauchier L, Bisson A, Bodin A. Heart failure with preserved ejection fraction and atrial fibrillation: recent advances and open questions. BMC Med. 2023;21(1):54. https:\/\/doi.org\/10.1186\/s12916-023-02764-3. Epub 2023\/02\/15.","journal-title":"BMC Med"},{"issue":"9","key":"7892_CR3","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s00392-024-02396-4","volume":"113","author":"S von Haehling","year":"2024","unstructured":"von Haehling S, Assmus B, Bekfani T, et al. Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment. Clinical research in cardiology. official J German Cardiac Soc. 2024;113(9):1287\u2013305. https:\/\/doi.org\/10.1007\/s00392-024-02396-4. Epub 2024\/04\/11.","journal-title":"official J German Cardiac Soc"},{"key":"7892_CR4","doi-asserted-by":"publisher","unstructured":"Sutanto H, Dobrev D, Heijman J. Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and cardiac arrhythmias. Int J Mol Sci. 2021;22(16). . https:\/\/doi.org\/10.3390\/ijms22168994","DOI":"10.3390\/ijms22168994"},{"issue":"1","key":"7892_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2023.04.019","volume":"82","author":"RJ Mentz","year":"2023","unstructured":"Mentz RJ, Ward JH, Hernandez AF, et al. Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure. J Am Coll Cardiol. 2023;82(1):1\u201312. https:\/\/doi.org\/10.1016\/j.jacc.2023.04.019. Epub 2023\/05\/22.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"7892_CR6","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(12):1089\u201398. Epub 2022\/08\/27. doi: 10.1056\/NEJMoa2206286. PubMed PMID: 36027570.","journal-title":"N Engl J Med"},{"issue":"5","key":"7892_CR7","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s10557-022-07371-7","volume":"37","author":"JA Requena-Ibanez","year":"2023","unstructured":"Requena-Ibanez JA, Santos-Gallego CG, Zafar MU, Badimon JJ. SGLT2-Inhibitors on HFpEF Patients. Role of Ejection Fraction. Cardiovasc Drugs Ther. 2023;37(5):989\u201396. https:\/\/doi.org\/10.1007\/s10557-022-07371-7. Epub 2022\/08\/04.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7892_CR8","doi-asserted-by":"publisher","unstructured":"Aranda JF, Ram\u00edrez CM, Mittelbrunn M. Inflammaging, a targetable pathway for preventing cardiovascular diseases. Cardiovascular Res. 2024. https:\/\/doi.org\/10.1093\/cvr\/cvae240","DOI":"10.1093\/cvr\/cvae240"},{"key":"7892_CR9","doi-asserted-by":"publisher","unstructured":"Bertaud A, Joshkon A, Heim X et al. Signaling pathways and potential therapeutic strategies in cardiac fibrosis. Int J Mol Sci. 2023;24(2). https:\/\/doi.org\/10.3390\/ijms24021756","DOI":"10.3390\/ijms24021756"},{"issue":"1","key":"7892_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41572-022-00347-9","volume":"8","author":"B Brundel","year":"2022","unstructured":"Brundel B, Ai X, Hills MT, Kuipers MF, Lip GYH, de Groot NMS. Atrial fibrillation. Nat reviews Disease primers. 2022;8(1):21. https:\/\/doi.org\/10.1038\/s41572-022-00347-9. Epub 2022\/04\/09.","journal-title":"Nat reviews Disease primers"},{"issue":"11","key":"7892_CR11","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1161\/circresaha.119.313572","volume":"124","author":"MA Pfeffer","year":"2019","unstructured":"Pfeffer MA, Shah AM, Borlaug BA. Heart Failure With Preserved Ejection Fraction In Perspective. Circul Res. 2019;124(11):1598\u2013617. https:\/\/doi.org\/10.1161\/circresaha.119.313572. Epub 2019\/05\/24.","journal-title":"Circul Res"},{"key":"7892_CR12","doi-asserted-by":"crossref","unstructured":"Giannitsi S, Bougiakli M, Bechlioulis A, Kotsia A, Michalis LK. Naka KKJTaicd. 6-minute walking test: a useful tool in the management of heart failure patients. 2019;13:1753944719870084.","DOI":"10.1177\/1753944719870084"},{"issue":"5","key":"7892_CR13","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1161\/circoutcomes.115.001958","volume":"8","author":"JA Spertus","year":"2015","unstructured":"Spertus JA, Jones PG. Development and Validation of a Short Version of the Kansas City Cardiomyopathy Questionnaire. Circulation Cardiovasc Qual outcomes. 2015;8(5):469\u201376. https:\/\/doi.org\/10.1161\/circoutcomes.115.001958. Epub 2015\/08\/27.","journal-title":"Circulation Cardiovasc Qual outcomes"},{"issue":"5","key":"7892_CR14","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.62347\/khqw5375","volume":"16","author":"B Xie","year":"2024","unstructured":"Xie B, Gao Q, Wang Y, Du J, He Y. Effect of sacubitril-valsartan on left ventricular remodeling and NT-proBNP in patients with heart failure complicated with hypertension and reduced ejection fraction. Am J translational Res. 2024;16(5):1935\u201344. https:\/\/doi.org\/10.62347\/khqw5375. Epub 2024\/06\/17.","journal-title":"Am J translational Res"},{"issue":"20","key":"7892_CR15","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1136\/heartjnl-2017-311295","volume":"103","author":"JSS Singh","year":"2017","unstructured":"Singh JSS, Burrell LM, Cherif M, Squire IB, Clark AL, Lang CC. Sacubitril\/valsartan: beyond natriuretic peptides. Heart. 2017;103(20):1569\u201377. https:\/\/doi.org\/10.1136\/heartjnl-2017-311295. Epub 2017\/07\/10.","journal-title":"Heart"},{"issue":"1","key":"7892_CR16","doi-asserted-by":"publisher","first-page":"30764","DOI":"10.1038\/s41598-024-80829-w","volume":"14","author":"HX Ma","year":"2024","unstructured":"Ma HX, Wu K, Dong FH, Cai BK, Wu D, Lu HY. Effects of Empagliflozin and Dapagliflozin in alleviating cardiac fibrosis through SIRT6-mediated oxidative stress reduction. Sci Rep. 2024;14(1):30764. https:\/\/doi.org\/10.1038\/s41598-024-80829-w. Epub 2024\/12\/28.","journal-title":"Sci Rep"},{"issue":"16","key":"7892_CR17","doi-asserted-by":"publisher","first-page":"e016270","DOI":"10.1161\/jaha.120.016270","volume":"9","author":"M Packer","year":"2020","unstructured":"Packer M, Molecular. Cellular, and Clinical Evidence That Sodium-Glucose Cotransporter 2 Inhibitors Act as Neurohormonal Antagonists When Used for the Treatment of Chronic Heart Failure. J Am Heart Association. 2020;9(16):e016270. https:\/\/doi.org\/10.1161\/jaha.120.016270. Epub 2020\/08\/14.","journal-title":"J Am Heart Association"},{"key":"7892_CR18","doi-asserted-by":"publisher","unstructured":"Yang Z, Li T, Xian J et al. SGLT2 inhibitor dapagliflozin attenuates cardiac fibrosis and inflammation by reverting the HIF-2\u03b1 signaling pathway in arrhythmogenic cardiomyopathy. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2022;36(7):e22410. https:\/\/doi.org\/10.1096\/fj.202200243R","DOI":"10.1096\/fj.202200243R"},{"issue":"1","key":"7892_CR19","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/s12933-024-02415-8","volume":"23","author":"A Albulushi","year":"2024","unstructured":"Albulushi A, Tanoh DB, Almustafa A, Al Matrooshi N, Zolty R, Lowes B. Comparative effects of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors on heart failure with preserved ejection fraction in diabetic patients: a meta-analysis. Cardiovasc Diabetol. 2024;23(1):324. https:\/\/doi.org\/10.1186\/s12933-024-02415-8. Epub 2024\/09\/01.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"7892_CR20","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1002\/ehf2.14186","volume":"10","author":"L Ortega-Paz","year":"2023","unstructured":"Ortega-Paz L, Crist\u00f3bal H, Ortiz-Perez JT, et al. Direct actions of dapagliflozin and interactions with LCZ696 and spironolactone on cardiac fibroblasts of patients with heart failure and reduced ejection fraction. ESC heart Fail. 2023;10(1):453\u201364. PubMed PMID: 36303443; PubMed Central PMCID: PMCPMC9871706.","journal-title":"ESC heart Fail"},{"issue":"2","key":"7892_CR21","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s10557-025-07714-0","volume":"40","author":"P Severino","year":"2026","unstructured":"Severino P, D\u2019Amato A, Myftari V, et al. Early in-hospital use of SGLT2i in heart failure patients with ischemic etiology. Cardiovasc Drugs Ther. 2026;40(2):531\u201342. https:\/\/doi.org\/10.1007\/s10557-025-07714-0. Epub 2025\/05\/15.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7892_CR22","doi-asserted-by":"publisher","first-page":"1341601","DOI":"10.3389\/fcvm.2024.1341601","volume":"11","author":"S Iwamiya","year":"2024","unstructured":"Iwamiya S, Ihara K, Furukawa T, Sasano T. Sacubitril\/valsartan attenuates atrial conduction disturbance and electrophysiological heterogeneity with ameliorating fibrosis in mice. Front Cardiovasc Med. 2024;11:1341601. https:\/\/doi.org\/10.3389\/fcvm.2024.1341601. Epub 2024\/02\/05.","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"7892_CR23","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00395-023-01022-0","volume":"119","author":"A Paasche","year":"2024","unstructured":"Paasche A, Wiedmann F, Kraft M, et al. Acute antiarrhythmic effects of SGLT2 inhibitors-dapagliflozin lowers the excitability of atrial cardiomyocytes. Basic Res Cardiol. 2024;119(1):93\u2013112. https:\/\/doi.org\/10.1007\/s00395-023-01022-0. Epub 2024\/01\/04.","journal-title":"Basic Res Cardiol"},{"issue":"1","key":"7892_CR24","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/ehf2.14169","volume":"10","author":"C Dai","year":"2023","unstructured":"Dai C, Kong B, Shuai W, et al. Dapagliflozin reduces pulmonary vascular damage and susceptibility to atrial fibrillation in right heart disease. ESC heart Fail. 2023;10(1):578\u201393. https:\/\/doi.org\/10.1002\/ehf2.14169. Epub 2022\/11\/13.","journal-title":"ESC heart Fail"},{"issue":"2","key":"7892_CR25","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s10557-025-07706-0","volume":"40","author":"W Li","year":"2026","unstructured":"Li W, Feng W, Wang J, Song Y, Liang X, Xue S. The FUNCTION Study: A Randomized Controlled Trial on the Efficacy of Sacubitril\/Valsartan on the Success Rate of Catheter Ablation for Nonparoxysmal Atrial Fibrillation. Cardiovasc Drugs Ther. 2026;40(2):517\u201329. https:\/\/doi.org\/10.1007\/s10557-025-07706-0. Epub 2025\/05\/07.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"6","key":"7892_CR26","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1007\/s10557-024-07653-2","volume":"39","author":"B Xu","year":"2025","unstructured":"Xu B, Zhang T, Kang B, et al. Investigating Sodium-Glucose Cotransporter 2 Inhibitors Versus Other Glucose-Lowering Drugs on Ventricular Arrhythmias or Sudden Cardiac Death Using the US FDA Adverse Event Reporting System. Cardiovasc Drugs Ther. 2025;39(6):1309\u201319. https:\/\/doi.org\/10.1007\/s10557-024-07653-2. Epub 2024\/12\/04.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7892_CR27","doi-asserted-by":"publisher","first-page":"101766","DOI":"10.1016\/j.ijcha.2025.101766","volume":"60","author":"X Wang","year":"2025","unstructured":"Wang X, Hu Z, Yao Y, Maimaitijiang P, Chen A, Zheng L. Changes in heart rate variability parameters following pulsed-field ablation in patients with atrial fibrillation: A systematic review and meta-analysis HRV changes after pulsed-field ablation in AF. Int J Cardiol Heart vasculature. 2025;60:101766. PubMed PMID: 40837616; PubMed Central PMCID: PMCPMC12363479.","journal-title":"Int J Cardiol Heart vasculature"},{"issue":"2025","key":"7892_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1109\/embc58623.2025.11254067","volume":"IEEE Eng Med Bi","author":"D Filos","year":"2025","unstructured":"Filos D, Toumpourleka M, Tachmatzidis D, Vassilikos V, Chouvarda I. P-Wave spatial variability in 12-Lead ECG predicts temporal changes in atrial fibrillation. Annual Int Conf IEEE Eng Med biology Soc. 2025;IEEE Eng Med Biol Soc Annual Int Conf(2025):1\u20134. . https:\/\/doi.org\/10.1109\/embc58623.2025.11254067","journal-title":"Annual Int Conf IEEE Eng Med biology Soc"},{"issue":"4","key":"7892_CR29","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s10557-023-07434-3","volume":"38","author":"JH Amesz","year":"2024","unstructured":"Amesz JH, Langmuur SJJ, Epskamp N, et al. Acute Biomechanical Effects of Empagliflozin on Living Isolated Human Heart Failure Myocardium. Cardiovasc Drugs Ther. 2024;38(4):659\u201366. https:\/\/doi.org\/10.1007\/s10557-023-07434-3. Epub 2023\/02\/14.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7892_CR30","doi-asserted-by":"publisher","unstructured":"Battistoni I, Pongetti G, Falchetti E, et al. Safety and efficacy of dapagliflozin in patients with heart failure with reduced ejection fraction: Multicentre retrospective study on echocardiographic parameters and biomarkers of heart congestion. J Clin Med. 2024;13(12). https:\/\/doi.org\/10.3390\/jcm13123522.","DOI":"10.3390\/jcm13123522"},{"issue":"5","key":"7892_CR31","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00395-024-01067-9","volume":"119","author":"S Chen","year":"2024","unstructured":"Chen S, Wang Q, Bakker D, et al. Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2. Basic Res Cardiol. 2024;119(5):751\u201372. https:\/\/doi.org\/10.1007\/s00395-024-01067-9. Epub 2024\/07\/24.","journal-title":"Basic Res Cardiol"},{"issue":"7","key":"7892_CR32","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.4239\/wjd.v15.i7.1518","volume":"15","author":"PL Yu","year":"2024","unstructured":"Yu PL, Yu Y, Li S, Mu BC, Nan MH, Pang M. Dapagliflozin in heart failure and type 2 diabetes: Efficacy, cardiac and renal effects, safety. World J diabetes. 2024;15(7):1518\u201330. https:\/\/doi.org\/10.4239\/wjd.v15.i7.1518. Epub 2024\/08\/05.","journal-title":"World J diabetes"},{"issue":"2","key":"7892_CR33","doi-asserted-by":"publisher","first-page":"135","DOI":"10.5114\/aic.2021.107491","volume":"17","author":"J Nessler","year":"2021","unstructured":"Nessler J. Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction - a practical approach. Postepy w kardiologii interwencyjnej\u2009=\u2009Advances. interventional Cardiol. 2021;17(2):135\u201340. https:\/\/doi.org\/10.5114\/aic.2021.107491. Epub 2021\/08\/18.","journal-title":"interventional Cardiol"},{"issue":"1","key":"7892_CR34","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s43044-024-00508-z","volume":"76","author":"A Hassan","year":"2024","unstructured":"Hassan A, Samaan K, Asfour A, Baghdady Y, Samaan AA. Ventricular remodeling and hemodynamic changes in heart failure patients with non-ischemic dilated cardiomyopathy following dapagliflozin initiation. Egypt Heart J (EHJ): Official Bull Egypt Soc Cardiol. 2024;76(1):76. . https:\/\/doi.org\/10.1186\/s43044-024-00508-z","journal-title":"Egypt Heart J (EHJ): Official Bull Egypt Soc Cardiol"},{"key":"7892_CR35","doi-asserted-by":"publisher","first-page":"1097066","DOI":"10.3389\/fcvm.2023.1097066","volume":"10","author":"J Jiang","year":"2023","unstructured":"Jiang J, Gao J, Zhang X, et al. Combined treatment with sacubitril\/valsartan plus dapagliflozin in patients affected by heart failure with reduced ejection fraction. Front Cardiovasc Med. 2023;10:1097066. https:\/\/doi.org\/10.3389\/fcvm.2023.1097066. Epub 2023\/04\/11.","journal-title":"Front Cardiovasc Med"},{"key":"7892_CR36","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.bbrc.2023.05.094","volume":"671","author":"L Luo","year":"2023","unstructured":"Luo L, Dong B, Zhang J, et al. Dapagliflozin restores diabetes-associated decline in vasculogenic capacity of endothelial progenitor cells via activating AMPK-mediated inhibition of inflammation and oxidative stress. Biochem Biophys Res Commun. 2023;671:205\u201314. . https:\/\/doi.org\/10.1016\/j.bbrc.2023.05.094","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"7892_CR37","doi-asserted-by":"publisher","first-page":"238","DOI":"10.31083\/j.rcm2307238","volume":"23","author":"M Nikolic","year":"2022","unstructured":"Nikolic M, Srejovic I, Jovic JJ, et al. Sacubitril\/valsartan in Heart Failure and Beyond-From Molecular Mechanisms to Clinical Relevance. Rev Cardiovasc Med. 2022;23(7):238. https:\/\/doi.org\/10.31083\/j.rcm2307238. Epub 2022\/06\/24.","journal-title":"Rev Cardiovasc Med"},{"key":"7892_CR38","doi-asserted-by":"publisher","unstructured":"Mauriello A, Ascrizzi A, Roma AS et al. Effects of heart failure therapies on atrial fibrillation: biological and clinical perspectives. Antioxidants (Basel, Switzerland). 2024;13(7). https:\/\/doi.org\/10.3390\/antiox13070806.","DOI":"10.3390\/antiox13070806"},{"issue":"12","key":"7892_CR39","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1002\/ejhf.2722","volume":"24","author":"M Yang","year":"2022","unstructured":"Yang M, Butt JH, Kondo T, et al. Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril\/valsartan. Eur J Heart Fail. 2022;24(12):2307\u201319. https:\/\/doi.org\/10.1002\/ejhf.2722. Epub 2022\/11\/08.","journal-title":"Eur J Heart Fail"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07892-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-026-07892-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07892-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:29:26Z","timestamp":1789522166000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-026-07892-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["7892"],"URL":"https:\/\/doi.org\/10.1007\/s10557-026-07892-5","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"9 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Institutional Review Board and Research Ethics Committee of Nantong First People\u2019s Hospital, and was conducted in accordance to the tenets of the Declaration of Helsinki. The informed consent was waived by the ethics board.","order":1,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Clinical Trial Number","group":{"name":"EthicsHeading","label":"Declarations"}}]}}